Based at Liverpool Science Park, NasoGastric Feeding Solutions (NGFS) is focused on developing cutting edge enteral access technologies, designed to assist the clinicians who use them and to benefit patients with life threatening conditions.

The £750,000 of investment secured will enable NGFS’s new DoubleCHEK™ device to be manufactured in the UK and initiate commercialisation through a UK-wide sales roll out in Q2 2021. The investment will also be used to obtain FDA approval ahead of US expansion, being led by NGFS’s team in Chicago, Illinois.

George Gallagher, CEO, at NGFS, said:

“We are delighted to have secured the investment both from private investors and the British Business Bank during what is a difficult time for many early-stage companies.

“This vital support will help us to introduce DoubleCHEK™ to more hospitals both in the UK and USA and to save lives from an entirely preventable problem.”

DoubleCHEK™ uses dual indicators, CO2 and pH, to prevent the misplacement of feeding tubes into the lungs. This misplacement is known as a ‘never event’ in the NHS, which means that it is wholly preventable if current national guidance is followed properly, but it is still surprisingly common.

DoubleCHEK™ is the brainchild of George Gallagher, whose personal health experiences inspired his company’s unique invention. Having been working on developing highly technological naso gastric feeding tube solutions since 2011, NGFS has since worked closely with end users at the Royal Liverpool University Hospital, the University of Liverpool and Alder Hey Children’s Hospital to refine and simplify their latest innovation.

These studies have resulted in the robust DoubleCHEK™ device, which has been both CE marked and included on the NHS framework. DoubleCHEK™ is just the first product in a line of many planned to be released by NGFS over the next two years.

As well as expanding its product range, the SME is looking to grow its team and is currently recruiting for four positions across its quality and regulation, product and technical admin departments.

Having navigated their way through a challenging economic climate during the pandemic, NGFS have continued to prosper, not only through receiving significant investment, but by becoming more efficient due to their operational migration to using international video calls to undertake product demos.

They are now planning to expand their presence in Liverpool later this year, having benefitted from growing out of the Bio Medical Hub in Liverpool Science Park (LSP) over the past nine years. Being surrounded by like-minded individuals and other leading Med Tech companies within the LSP community has enabled NGFS to make valuable connections and has strengthened their investment links.

For more information about NasoGastric Feeding Solutions and DoubleCHEK™, please visit: https://ngf-s.com/